NBT Bank N A NY Has $826,000 Holdings in Becton, Dickinson and Company (NYSE:BDX)

NBT Bank N A NY cut its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 4.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,641 shares of the medical instruments supplier’s stock after selling 160 shares during the period. NBT Bank N A NY’s holdings in Becton, Dickinson and Company were worth $826,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Bank of Jackson Hole Trust acquired a new stake in shares of Becton, Dickinson and Company in the 4th quarter valued at approximately $25,000. Sierra Ocean LLC acquired a new stake in shares of Becton, Dickinson and Company in the 4th quarter valued at approximately $29,000. Ashton Thomas Securities LLC acquired a new stake in shares of Becton, Dickinson and Company in the 3rd quarter valued at approximately $33,000. Kennebec Savings Bank acquired a new stake in shares of Becton, Dickinson and Company in the 3rd quarter valued at approximately $46,000. Finally, Versant Capital Management Inc raised its position in shares of Becton, Dickinson and Company by 54.1% in the 4th quarter. Versant Capital Management Inc now owns 208 shares of the medical instruments supplier’s stock valued at $47,000 after acquiring an additional 73 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 2,838 shares of the firm’s stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $223.33, for a total value of $633,810.54. Following the completion of the transaction, the executive vice president now directly owns 6,141 shares of the company’s stock, valued at approximately $1,371,469.53. This trade represents a 31.61 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David Shan sold 500 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total transaction of $120,000.00. Following the completion of the transaction, the executive vice president now directly owns 5,741 shares of the company’s stock, valued at $1,377,840. This represents a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,423 shares of company stock valued at $1,239,780 in the last ninety days. 0.36% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $227.09 on Tuesday. The stock has a market capitalization of $65.21 billion, a P/E ratio of 37.72, a P/E/G ratio of 1.63 and a beta of 0.35. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $251.99. The company has a 50 day moving average of $232.99 and a 200-day moving average of $232.65. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its board has authorized a stock repurchase plan on Tuesday, January 28th that permits the company to repurchase 10,000,000 shares. This repurchase authorization permits the medical instruments supplier to repurchase shares of its stock through open market purchases. Shares repurchase plans are usually a sign that the company’s management believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be paid a dividend of $1.04 per share. The ex-dividend date is Monday, March 10th. This represents a $4.16 annualized dividend and a dividend yield of 1.83%. Becton, Dickinson and Company’s dividend payout ratio is currently 69.10%.

Wall Street Analysts Forecast Growth

Several analysts have commented on BDX shares. Piper Sandler raised their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, January 28th. Barclays raised their target price on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Finally, StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Wednesday, March 5th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $278.29.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.